Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Rating of "Buy" by Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $211.13.

KRYS has been the subject of several recent analyst reports. Citigroup reduced their target price on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research report on Friday, May 16th. Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday. Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. Finally, Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th.

Krystal Biotech Stock Down 2.6%

Shares of NASDAQ:KRYS traded down $3.70 during midday trading on Wednesday, reaching $138.88. 418,422 shares of the company traded hands, compared to its average volume of 286,984. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $219.34. The firm has a market capitalization of $4.01 billion, a price-to-earnings ratio of 33.38 and a beta of 0.65. The firm's fifty day moving average price is $140.66 and its two-hundred day moving average price is $157.65.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The business had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Analysts forecast that Krystal Biotech will post 6.14 earnings per share for the current year.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of KRYS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after purchasing an additional 365,304 shares in the last quarter. Nuveen LLC purchased a new position in shares of Krystal Biotech in the 1st quarter worth about $42,223,000. Norges Bank purchased a new position in shares of Krystal Biotech in the 4th quarter worth about $34,391,000. Braidwell LP boosted its holdings in Krystal Biotech by 99.9% during the 1st quarter. Braidwell LP now owns 400,744 shares of the company's stock valued at $72,254,000 after acquiring an additional 200,244 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in Krystal Biotech during the 1st quarter valued at about $33,455,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).